CYP2C19 – Medxy AI

CYP2D6 与 CYP2C19 遗传变异对文拉法辛疗效的影响：来自挪威和英国队列的研究洞见

Impact of CYP2D6 and CYP2C19 Genetic Variations on Venlafaxine Treatment Outcomes: Insights from Norwegian and UK Cohorts

By MedXY 10/17/2026

This article reviews a large retrospective study revealing significant associations between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure, highlighting the potential for genotype-guided personalized antidepressant therapy.

Gastroenterology General Surgery news

Impact of CYP2C19 Polymorphisms on Medical and Surgical Management of GERD: Implications for Personalized Therapy

By MedXY 08/25/2026

A study reveals a higher prevalence of rapid CYP2C19 metabolizer phenotypes in GERD patients undergoing surgery versus medical therapy, supporting tailored proton pump inhibitor dosing and timely surgical referral.

Diabetes & Endocrinology Neurology news

High Insulin Resistance Blunts the Superiority of Ticagrelor Over Clopidogrel in Minor Stroke Patients with CYP2C19 Mutations

By MedXY 01/22/2026

A post hoc analysis of the CHANCE-2 trial suggests that the clinical benefit of ticagrelor over clopidogrel for secondary stroke prevention in CYP2C19 loss-of-function carriers is significantly attenuated in patients with high insulin resistance.